Following enrollment, participants are assigned to either the intervention or control group at a 1:1 ratio using block randomization. The randomization sequence is generated and maintained by a second study coordinator—who has no role in patient assessment, data collection, or statistical analysis—using the Randomizer.org website. To ensure allocation concealment, group assignment codes (A and B) are placed in opaque, sealed, and sequentially numbered envelopes; this information is disclosed only to a designated staff member who is not involved in treatment, outcome assessment, or data analysis. This individual is responsible for preparing and administering the intervention to the patient. The Spirulina supplement and the placebo are provided in containers that are identical in shape, size, and appearance, distinguished solely by codes A and B; consequently, patients, healthcare staff, outcome assessors, and the data analyst remain unaware of group assignments, thereby fully maintaining the study's double-blind design. Ultimately, 65 patients will be enrolled in each group.
To maintain allocation concealment, following the generation of a randomization sequence using block randomization, group allocation codes (A and B) were placed in opaque, sealed, and numbered envelopes by an independent individual who was not involved in treatment, outcome assessment, or data analysis. The Spirulina supplement and placebo were prepared in identical containers and labeled solely with codes A and B; consequently, patients, healthcare staff, outcome assessors, and the data analyst remained unaware of the group allocations, ensuring the study's double-blind design was fully maintained.